Body Composition as a Predictor of Toxicity and Prognosis in Patients with Diffuse Large B-Cell Lymphoma Receiving R-CHOP Immunochemotherapy

Body Composition as a Predictor of Toxicity and Prognosis in Patients with Diffuse Large B-Cell Lymphoma Receiving R-CHOP Immunochemotherapy

Background: Our study measured the body composition of Diffuse large B-cell lymphoma (DLBCL) patients receiving rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) regimen by computed tomographic (CT) and assessed their correlation with treatment-related toxicity and ot...

Full description

Bibliographic Details
Main Authors: Jiaxun Guo, Panpan Cai, Pengfei Li, Cong Cao, Jing Zhou, Lina Dong, Yan Yang, Qijia Xuan, Jingxuan Wang, Qingyuan Zhang
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Current Oncology
Subjects:
diffuse large B-cell lymphoma
immunochemotherapy
survival
sarcopenia
toxicity
Online Access:https://www.mdpi.com/1718-7729/28/2/126

Internet

https://www.mdpi.com/1718-7729/28/2/126

Similar Items